Lips CJ - Search Results

1

Somatic mutations of the RET proto-oncogene are not required for tumor development in multiple endocrine neoplasia type 2 (MEN 2) gene carriers.

Landsvater RM, de Wit MJ, Zewald RA, Hofstra RM, Buys CH, Ploos van Amstel HK, Höppener JW, Lips CJ. Landsvater RM, et al. Among authors: lips cj. Cancer Res. 1996 Nov 1;56(21):4853-5. Cancer Res. 1996. PMID: 8895732

2

Tissue selectivity in multiple endocrine neoplasia type 1-associated tumorigenesis.

Gracanin A, Dreijerink KM, van der Luijt RB, Lips CJ, Höppener JW. Gracanin A, et al. Among authors: lips cj. Cancer Res. 2009 Aug 15;69(16):6371-4. doi: 10.1158/0008-5472.CAN-09-0678. Epub 2009 Aug 4. Cancer Res. 2009. PMID: 19654304 Review.

3

Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A.

Lips CJ, Landsvater RM, Höppener JW, Geerdink RA, Blijham G, van Veen JM, van Gils AP, de Wit MJ, Zewald RA, Berends MJ, et al. Lips CJ, et al. N Engl J Med. 1994 Sep 29;331(13):828-35. doi: 10.1056/NEJM199409293311302. N Engl J Med. 1994. PMID: 7915822 Free article.

4

Mutation analysis of the RET proto-oncogene in Dutch families with MEN 2A, MEN 2B and FMTC: two novel mutations and one de novo mutation for MEN 2A.

Landsvater RM, Jansen RP, Hofstra RM, Buys CH, Lips CJ, Ploos van Amstel HK. Landsvater RM, et al. Among authors: lips cj. Hum Genet. 1996 Jan;97(1):11-4. doi: 10.1007/BF00218825. Hum Genet. 1996. PMID: 8557249

5

RET mutation screening in familial cutaneous lichen amyloidosis and in skin amyloidosis associated with multiple endocrine neoplasia.

Hofstra RM, Sijmons RH, Stelwagen T, Stulp RP, Kousseff BG, Lips CJ, Steijlen PM, Van Voorst Vader PC, Buys CH. Hofstra RM, et al. Among authors: lips cj. J Invest Dermatol. 1996 Aug;107(2):215-8. doi: 10.1111/1523-1747.ep12329651. J Invest Dermatol. 1996. PMID: 8757765 Free article.

6

RET receptor tyrosine kinase gene mutations: molecular biological, physiological and clinical aspects.

Höppener JW, Lips CJ. Höppener JW, et al. Among authors: lips cj. Eur J Clin Invest. 1996 Aug;26(8):613-24. doi: 10.1111/j.1365-2362.1996.tb02144.x. Eur J Clin Invest. 1996. PMID: 8872055 Review. No abstract available.

7

Exclusion of the phosphatidylinositol-specific phospholipase C beta 3 (PLC beta 3) gene as candidate for the multiple endocrine neoplasia type 1 (MEN 1) gene.

de Wit MJ, Landsvater RM, Sinke RJ, Geurts van Kessel A, Lips CJ, Höppener JW. de Wit MJ, et al. Among authors: lips cj. Hum Genet. 1997 Jan;99(1):133-7. doi: 10.1007/s004390050327. Hum Genet. 1997. PMID: 9003511

8

Exclusion of the nuclear factor-kappa B3 (REL A) gene as candidate for the multiple endocrine neoplasia type 1 (MEN 1) gene.

Landsvater RM, de Wit MJ, Peterson LF, Sinke RJ, Geurts van Kessel A, Lips CJ, Höppener JW. Landsvater RM, et al. Among authors: lips cj. Biochem Mol Med. 1997 Feb;60(1):76-9. doi: 10.1006/bmme.1996.2561. Biochem Mol Med. 1997. PMID: 9066984

9

Internally shortened menin protein as a consequence of alternative RNA splicing due to a germline deletion in the multiple endocrine neoplasia type 1 gene.

Roijers JF, Apel T, Neumann HP, Arnim UV, Lips CJ, Hoppener JW. Roijers JF, et al. Among authors: lips cj. Int J Mol Med. 2000 Jun;5(6):611-4. doi: 10.3892/ijmm.5.6.611. Int J Mol Med. 2000. PMID: 10812010

10

Criteria for mutation analysis in MEN 1-suspected patients: MEN 1 case-finding.

Roijers JF, de Wit MJ, van der Luijt RB, Ploos van Amstel HK, Höppener JW, Lips CJ. Roijers JF, et al. Among authors: lips cj. Eur J Clin Invest. 2000 Jun;30(6):487-92. doi: 10.1046/j.1365-2362.2000.00664.x. Eur J Clin Invest. 2000. PMID: 10849016

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

195 results

Search Page

Filters